New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that ...

Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

The findings could significantly change the ... Lung Cancer Test Predicts Survival in Early Stages Better Than Current Methods Jan. 9, 2025 — Researchers have shown that a test called ORACLE can ...

Lung Cancer Test Predicts Survival in Early Stages Better Than Current Methods Jan. 9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for ...

SAVANNAH and ORCHARD Phase II trials show the addition of Orpathys or Datroway to Tagrisso upon disease progression demonstrates strong clinical activity New study results presented at the European ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Every year, 1.8 million people lose their lives to lung cancer, making it one of the deadliest diseases and one of the leading causes of cancer-related deaths worldwide. A major reason for the high ...